Please register and get access to full articles.
Welcome to our blog – a place to discuss and exchange thoughts and ideas about iX-7 Asset Management SA, the stock markets and all matters relating to wealth management.
Bayer's rock-bottom sentiment and valuation continue to offer a credible, de-risked entry point, in our view. The stock trades below 9x 2023E P/E. Bayer's relatively cautious guidance for 2022 is too conservative, as agro markets in particular have sustainably rebounded, backed by strong crop prices. Pharma: while Eylea and Xarelto are faced with patent loss, their respective sales are holding up better than expected so far, and Bayer has a broader pipeline of new compounds with >EUR5bn of peak sales. Any kind of change can only be good news: litigation progress, activism, ESG improvement.
Catalysts:
Knowledge is power.